The establishment of reference systems for the standardization of hemoglobin A2 (HbA2) and fetal hemoglobin (HbF), both critical for improving diagnostic accuracy in conditions such as β-thalassemia and sickle cell disease, are described. Efforts were led by the IFCC and other groups to address and reduce the variability in laboratory measurements of these hemoglobins. This document outlines the production of certified reference materials (CRMs) for HbA2 and the development of a reference measurement procedure using isotope dilution mass spectrometry. Similarly, standardizing HbF is essential for supporting diagnostic and therapeutic strategies, particularly in managing sickle cell disease. HbF levels can predict disease outcomes and guide treatment plans. Significant challenges remain in achieving consistent measurement across laboratories, and the process for standardization for this minor hemoglobin has just begun. We are confident that the implementation of these reference systems will provide improved accuracy and traceability in the future.

Standardization of hemoglobin A2 and hemoglobin F: Achievements and perspectives / A. Mosca, C. Arsene, R. Paleari, P. Kaiser, K. Harteveld, Y. Daniel, C. Amano, A. Murakami, G. Auclair. - In: CLINICA CHIMICA ACTA. - ISSN 0009-8981. - 567:(2025 Feb 01), pp. 120087.1-120087.5. [10.1016/j.cca.2024.120087]

Standardization of hemoglobin A2 and hemoglobin F: Achievements and perspectives

A. Mosca
;
R. Paleari;
2025

Abstract

The establishment of reference systems for the standardization of hemoglobin A2 (HbA2) and fetal hemoglobin (HbF), both critical for improving diagnostic accuracy in conditions such as β-thalassemia and sickle cell disease, are described. Efforts were led by the IFCC and other groups to address and reduce the variability in laboratory measurements of these hemoglobins. This document outlines the production of certified reference materials (CRMs) for HbA2 and the development of a reference measurement procedure using isotope dilution mass spectrometry. Similarly, standardizing HbF is essential for supporting diagnostic and therapeutic strategies, particularly in managing sickle cell disease. HbF levels can predict disease outcomes and guide treatment plans. Significant challenges remain in achieving consistent measurement across laboratories, and the process for standardization for this minor hemoglobin has just begun. We are confident that the implementation of these reference systems will provide improved accuracy and traceability in the future.
Certified reference materials; Gene therapy; HbA(2); HbF; Reference intervals; Reference measurement procedure; Traceability; β-thalassemia
Settore BIOS-09/A - Biochimica clinica e biologia molecolare clinica
1-feb-2025
9-dic-2024
Article (author)
File in questo prodotto:
File Dimensione Formato  
A_70_2025_Std A2-F_CCA.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 541.58 kB
Formato Adobe PDF
541.58 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/1140536
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact